{"id":465480,"date":"2023-12-05T12:00:00","date_gmt":"2023-12-05T11:00:00","guid":{"rendered":"https:\/\/innovationorigins.com\/?p=465480"},"modified":"2023-12-05T12:00:00","modified_gmt":"2023-12-05T11:00:00","slug":"e1-4-million-for-development-of-synthetic-breast-tissue-after-surgery","status":"publish","type":"post","link":"https:\/\/ioplus.nl\/archive\/en\/e1-4-million-for-development-of-synthetic-breast-tissue-after-surgery\/","title":{"rendered":"\u20ac1.4 million for development of biomaterial for breast reconstruction after surgery"},"content":{"rendered":"\n

One in seven women will develop breast cancer at some point in their lives. More than 50 per cent opt for breast reconstruction. Eindhoven-based VivArt-X will work with partners over the next three years to create a synthetic material that helps restore healthy breast tissue after breast surgery. An amount of \u20ac1.4 million<\/a> has been earmarked for the project.<\/p>\n\n\n

<\/a>
<\/div><\/div>
Funding VivArt-X should improve life of women after breast-conserving surgery<\/div>
VivArt-X is developing a biodegradable biomaterial to regenerate tissue, with which the company can help patients with breast cancer better survive the transplanted fat. <\/div><\/div><\/div>\n\n\n

The Eindhoven startup will work with Smart BioMaterials Consortium (SBMC) and TU\/e for the next three years. The research could have a major impact on public health. The new personalised method, in which the body’s own cells form healthy breast tissue, should result in fewer reoperations, better recovery and a better quality of life after breast surgery.<\/p>\n\n\n\n

TU\/e is contributing its knowledge and facilities; SBMC will be responsible for accelerating product development and quality assurance. Screening of the new material and improvement of cell-material interactions will be carried out in SBMC’s development laboratory, on the TU\/e campus.<\/p>\n\n\n\n

VivArt-X was one of the winners of the Gerard & Anton Awards 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"

One in seven women will develop breast cancer at some point in their lives. More than 50 per cent opt for breast reconstruction. Eindhoven-based VivArt-X will work with partners over the next three years to create a synthetic material that helps restore healthy breast tissue after breast surgery. An amount of \u20ac1.4 million has been […]<\/p>\n","protected":false},"author":2589,"featured_media":494918,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[34665],"tags":[32312,82565,80822],"location":[6763],"article_type":[36684],"serie":[],"archives":[],"internal_archives":[],"reboot-archive":[],"class_list":["post-465480","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-borstkanker","tag-breast-cancer-6","tag-vivart-x","location-netherlands","article_type-news"],"blocksy_meta":[],"acf":{"subtitle":"Eindhoven-based VivArt-X will work with partners over the next three years to create a synthetic material that helps restore healthy breast tissue.","text_display_homepage":false},"author_meta":{"display_name":"Team IO","author_link":"https:\/\/ioplus.nl\/archive\/author\/erikdevries\/"},"featured_img":"https:\/\/ioplus.nl\/archive\/wp-content\/uploads\/2023\/12\/VivArt-X.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["Health<\/a>"],"unlinked":["Health<\/span>"]},"tags":{"linked":["Borstkanker<\/a>","breast cancer<\/a>","VivArt-X<\/a>"],"unlinked":["Borstkanker<\/span>","breast cancer<\/span>","VivArt-X<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on December 5, 2023","modified":"Updated on December 5, 2023"},"absolute_dates_time":{"created":"Posted on December 5, 2023 12:00 pm","modified":"Updated on December 5, 2023 12:00 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/465480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/users\/2589"}],"replies":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/comments?post=465480"}],"version-history":[{"count":0,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/465480\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media\/494918"}],"wp:attachment":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media?parent=465480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/categories?post=465480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/tags?post=465480"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/location?post=465480"},{"taxonomy":"article_type","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/article_type?post=465480"},{"taxonomy":"serie","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/serie?post=465480"},{"taxonomy":"archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/archives?post=465480"},{"taxonomy":"internal_archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/internal_archives?post=465480"},{"taxonomy":"reboot-archive","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/reboot-archive?post=465480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}